Trials / Completed
CompletedNCT00851955
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.
Conditions
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-12-01
- Completion
- 2011-11-01
- First posted
- 2009-02-26
- Last updated
- 2016-01-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00851955. Inclusion in this directory is not an endorsement.